| Benign | Low suspicion | Intermediate suspicion | High suspicion | ||||
---|---|---|---|---|---|---|---|---|
RF | SRF<lc(0.265) | lc≤SRF<0.5 | 0.5≤SRF<hc(0.784) | SRF≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 110 | 4 | 41 | 11 | 35 | 47 | 12 | 898 |
 | 96.5% | 3.5% | 78.8% | 21.2% | 42.7% | 57.3% | 1.3% | 98.7% |
LR | SLR<lc(0.267) | lc≤SLR<0.5 | 0.5≤SLR<hc(0.838) | SLR≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 123 | 17 | 13 | 16 | 42 | 81 | 20 | 846 |
 | 87.9% | 12.1% | 44.8% | 55.2% | 34.1% | 65.9% | 2.3% | 97.7% |
SVM | SSVM<lc(0.277) | lc≤SSVM<0.5 | 0.5≤SSVM<hc(0.850) | SSVM≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 115 | 16 | 23 | 16 | 35 | 71 | 25 | 857 |
 | 87.8% | 12.2% | 59.0% | 41.0% | 33.0% | 67.0% | 2.8% | 97.2% |
NET | SNET<lc(0.300) | lc≤SNET<0.5 | 0.5≤SNET<hc(0.820) | SNET≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 125 | 19 | 14 | 20 | 37 | 61 | 22 | 860 |
 | 86.8% | 13.2% | 41.2% | 58.8% | 34.8% | 65.2% | 2.3% | 97.7% |
ELM | SELM<lc(0.352) | lc≤SELM<0.5 | 0.5≤SELM<hc(0.783) | SELM≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 103 | 7 | 28 | 18 | 46 | 113 | 21 | 822 |
 | 93.6% | 6.4% | 60.9% | 39.1% | 29.0% | 71.0% | 2.5% | 97.5% |
KNN | SKNN<lc(0.305) | lc≤SKNN<0.5 | 0.5≤SKNN<hc(0.864) | SKNN≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 117 | 13 | 15 | 16 | 49 | 114 | 17 | 817 |
 | 90.0% | 10.0% | 48.4% | 51.6% | 30.1% | 69.9% | 2.0% | 98.0% |
NB | SNB<lc(0.188) | lc≤SNB<0.5 | 0.5≤SNB<hc(0.869) | SNB≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 138 | 45 | 15 | 25 | 18 | 67 | 27 | 823 |
 | 75.4% | 24.6% | 37.5% | 62.5% | 21.2% | 78.8% | 3.2% | 96.8% |
ADAB | SADAB<lc(0.286) | lc≤SADAB<0.5 | 0.5≤SADAB<hc(0.614) | SADAB≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 87 | 2 | 98 | 12 | 7 | 12 | 6 | 934 |
 | 97.8% | 2.2% | 89.1% | 10.9% | 36.9% | 63.1% | 0.6% | 99.4% |
LOG | SLOG<lc(0.317) | lc≤SLOG<0.5 | 0.5≤SLOG<hc(0.820) | SLOG≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 113 | 13 | 19 | 12 | 52 | 118 | 14 | 817 |
 | 89.7% | 10.3% | 61.3% | 38.7% | 30.6% | 69.4% | 1.7% | 98.3% |
LDA | SLDA<lc(0.256) | lc≤SLDA<0.5 | 0.5≤SLDA<hc(0.958) | SLDA≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 120 | 27 | 18 | 10 | 41 | 100 | 19 | 823 |
 | 81.6% | 18.4% | 64.3% | 35.7% | 29.1% | 70.9% | 2.3% | 97.7% |
Management | After a 6-month | After 3-month sonographic | Â | FNA biopsy | ||||
of thyroid | sonographic | follow-up or Fine Needle | FNA biopsy | or surgical | ||||
nodules | follow-up | Aspiration (FNA) biopsy | Â | treatment |